Komatsu Hirokazu
Department of Medical Oncology and Immunology, Nagoya City University of Medical Sciences.
Nihon Rinsho. 2010 Jun;68(6):1085-93.
Monoclonal antibody (MoAb) for cancer treatment has been greatly progressed during this decade. Six kinds of MoAbs are now in clinical use in Japan. Here we review on the development of MoAbs such as rituximab, bevacizumab and cetuximab. The characterization and the nomenclature of MoAb are also described. Panitumumab, a new MoAb targeting epithelial growth factor receptor(EGFR), and the resistance of colorectal cancer with KRAS mutation for anti-EGFR MoAbs are on recent topics. The concept of bevacizumab beyond progression (BBP) and the unfavorable results of bevacizumab in elder nonsmall cell lung carcinoma patients are so suggestive considering the strategy of the individualized cancer therapy. Finally, "drug lag" for the development of anti-cancer agents between Eastern and Western has to be discussed.
在过去十年中，用于癌症治疗的单克隆抗体（MoAb）取得了巨大进展。目前有六种单克隆抗体在日本临床使用。在此，我们回顾利妥昔单抗、贝伐单抗和西妥昔单抗等单克隆抗体的发展历程。同时也描述了单克隆抗体的特性和命名。帕尼单抗是一种靶向表皮生长因子受体（EGFR）的新型单克隆抗体，以及KRAS突变的结直肠癌对抗EGFR单克隆抗体的耐药性是近期的研究热点。贝伐单抗超越疾病进展（BBP）的概念以及贝伐单抗在老年非小细胞肺癌患者中的不良结果，对于个体化癌症治疗策略具有重要的启示意义。最后，必须讨论东西方抗癌药物研发中的“药物滞后”问题。
